[go: up one dir, main page]

WO2017163159A1 - Composition pharmaceutique biphasique d'insuline humaine - Google Patents

Composition pharmaceutique biphasique d'insuline humaine Download PDF

Info

Publication number
WO2017163159A1
WO2017163159A1 PCT/IB2017/051584 IB2017051584W WO2017163159A1 WO 2017163159 A1 WO2017163159 A1 WO 2017163159A1 IB 2017051584 W IB2017051584 W IB 2017051584W WO 2017163159 A1 WO2017163159 A1 WO 2017163159A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
pharmaceutical composition
human
derivative
protamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/051584
Other languages
English (en)
Inventor
Maharaj Kishen SAHIB
Shivraj SWAMI
Rekha INGOLE
Ganesh SANGLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wockhardt Ltd
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of WO2017163159A1 publication Critical patent/WO2017163159A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention provides an aqueous injectable biphasic pharmaceutical composition comprising 200IU/ml of insulin, insulin analogues or derivative thereof, wherein said composition comprises (i) solution of insulin, insulin analogue or derivative thereof, and (ii) crystals of insulin, insulin analogue or derivative thereof with protamine having particle size in range of 8 ⁇ and 20 ⁇ and optionally, (iii) one or more pharmaceutically acceptable excipients.
  • Diabetes mellitus is a metabolic disorder in which the ability to utilize glucose is more or less completely lost. It is a major chronic illness found in humans with many consequences. Some complications arising from long-standing diabetes are blindness, kidney failure and limb amputations. Insulin-dependent diabetes mellitus (IDDM) accounts for 10 to 15% of all cases of diabetes mellitus.
  • IDDM Insulin-dependent diabetes mellitus
  • NPH insulin is the most widely-used insulin preparation, constituting from 50 to 70 percent of the insulin used worldwide. It is a suspension of a microcrystalline complex of insulin, zinc, protamine and one or more phenolic preservatives. NPH insulin preparations are commercially available incorporating human insulin, pork insulin, beef insulin, or mixtures thereof. Also, NPH-like preparations of a monomeric insulin analogue, LysB298, ProB29-human insulin analogue, are known in the art. Therapy using currently-available NPH insulin preparations fails to provide the ideal "flat" pharmacokinetics necessary to maintain optimal fasting blood glucose for an extended period of time between meals. Consequently, treatment with NPH insulin can result in undesirably high levels of insulin in the blood, which may cause life-threatening hypoglycemia.
  • NPH insulin In absence of an ideal flat pharmacokinetics profile, the duration of action of NPH insulin is also not ideal.
  • a major problem with NPH therapy is the "dawn phenomenon" which is hyperglycemia that results from loss of effective glucose control overnight while the patient is sleeping.
  • PCT publication No. WO2003053460 discloses a pharmaceutical composition comprising crystals of insulin and protamine for control of blood glucose.
  • PCT publication No. WO1999/048520 discloses an injectable, protracted acting human insulin preparation.
  • PCT publication No. WO1988/002633 discloses protamine zinc insulin preparation.
  • PCT publication No. WO 2011/156476 discloses a basal insulin formulation comprising a solution or suspension of recombinant human insulin at a pH of between 3.5 and 4.5.
  • US Patent No. 5,461,031 discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative.
  • US Patent No. 5,547,930 discloses crystals of human insulin with protamine.
  • US Patent No. 8,263,551 discloses a pharmaceutical formulation which is a solution comprising an insulin, an insulin analog or an insulin derivative or a mixture thereof and a protamine salt.
  • the medicinal product Huminsulin 30/70 lOOIU/mL marketed by Eli Lilly is a biphasic isophane insulin injection containing 30% soluble insulin and 70% isophane insulin.
  • the medicinal product Mixtard marketed by Novo Nordisk is a dual-acting, biphasic formulation consisting of a premix of soluble fast-acting insulin human and isophane long-acting insulin.
  • Huminsulin 30/70 contains 100IU of human insulin in 1ml, which confer some discomfort as the patient need to administer several injections of insulin each day. Although this treatment regimen is accepted as effective, it has limitations. The repeated injection cause painful administration of insulin which leads to inconvenience to patients. As a result, patients don't comply adequately with the prescribed treatment regimens and are often improperly medicated.
  • an aqueous injectable biphasic pharmaceutical composition comprising 200IU/ml of insulin, insulin analogues or derivative thereof, wherein said composition comprises: (i) a solution of insulin, insulin analogue or derivative thereof, and (ii) crystals of insulin, insulin analogue or derivative thereof with protamine having particle size in range of 8 ⁇ and 20 ⁇ and optionally, (iii) one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml insulin composition comprising (i) a solution of insulin, insulin analogue or derivative thereof and (ii) crystals of insulin, insulin analogue or derivative thereof with protamine, when administered to a subject at the same dose.
  • the pharmaceutical composition has a pH in the range of 6.0 and 8.5.
  • the solution of insulin, insulin analogue or derivative thereof and the crystals of insulin, insulin analogue or derivative thereof with protamine are present in a volume proportion ranging from about 99:1 to 1 :99.
  • the solution of insulin, insulin analogue or derivative thereof and the crystals of insulin, insulin analogue or derivative thereof with protamine are present in the volume proportion of about 30:70.
  • the insulin, insulin analogue or derivative thereof are selected from the group comprising insulin human, insulin isophane (NPH), insulin lispro, insulin glulisine, insulin aspart, Gly(A21) human insulin, Gly(A21) Lys(B28) human insulin, Gly(A21) Lys(B28) Pro(B29) human insulin, Gly(A21) Asp(B28).
  • the insulin, insulin analogues or derivative thereof is insulin human.
  • the one or more pharmaceutically acceptable excipients comprise isotonic agent, complexing agent, buffer, preservative, pH modifying agent, stabilizing agent or mixture thereof.
  • the pharmaceutical composition is administered through subcutaneous, intravenous or intramuscular route to a subject.
  • the pharmaceutical composition is for use in the treatment of type I and type II diabetes mellitus.
  • an aqueous injectable biphasic pharmaceutical composition comprising 200IU/ml of insulin human, wherein said pharmaceutical composition comprises: (i) a solution of insulin human; (ii) crystals of insulin human with protamine having particle size in range of 8 ⁇ and 15 ⁇ ; and (iii) pharmaceutically acceptable excipient comprising m-cresol, phenol, glycerol and zinc or salts thereof; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml insulin composition comprising (i) a solution of insulin human and (ii) crystals of insulin human with protamine, when administered to a subject at the same dose.
  • a process of preparing an aqueous injectable biphasic pharmaceutical composition comprising 200IU/ml of insulin, insulin analogues or derivative thereof, wherein said pharmaceutical composition comprises: (i) a solution of insulin, insulin analogue or derivative thereof and (ii) crystals of insulin, insulin analogue or derivative thereof with protamine having particle size in range of 8 ⁇ and 20 ⁇ and optionally, (iii) one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml insulin composition comprising (i) a solution of insulin, insulin analogue or derivative thereof and (ii) crystals of insulin, insulin analogue or derivative thereof with protamine, when administered to a subject at the same dose; wherein said process comprises steps of: a.
  • preparing a suspension of protamine and insulin by dissolving the insulin, insulin analogue or derivative thereof, protamine, one or more pharmaceutically acceptable excipients and adjusting a pH of the suspension in a range of 7.2 to 7.5 by addition of IN HC1 or IN NaOH;
  • step (b) preparing the solution of insulin by dissolving insulin, insulin analogue or derivative thereof, one or more pharmaceutically acceptable excipients and adjusting the pH of the solution in the range of 7.2 to 7.5 by addition of IN HC1 or IN NaOH; and c. mixing about 70% suspension of step (a) with the about 30% solution of step (b) to obtain an aqueous injectable biphasic pharmaceutical composition.
  • an aqueous injectable biphasic pharmaceutical composition comprising 200IU/ml of insulin human, wherein said pharmaceutical composition comprises: (i) a solution of insulin human; (ii) crystals of insulin human with protamine having particle size in range of 8 ⁇ and 15 ⁇ ; and (iii) pharmaceutically acceptable excipient comprising m-cresol, phenol, glycerol and zinc or salts thereof, wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml insulin composition comprising (i) a solution of insulin human and (ii) crystals of insulin human with protamine, when administered to a subject at the same dose; wherein said process comprises steps of:
  • preparing a suspension of protamine and insulin human by dissolving insulin human, protamine, zinc or salts thereof, meta-cresol, phenol in water for injection and adjusting a pH of the suspension in a range of 7.2 to 7.5 by addition of IN HC1 or IN NaOH;
  • step (b) preparing the solution of insulin human by dissolving insulin human, phenol, m- cresol, glycerol and disodium hydrogen phosphate in water for injection and adjusting the pH of solution in the range of 7.2 to 7.5 by addition of IN HC1 or IN NaOH; and c. mixing about 70% of suspension of step (a) with 30% of solution of step (b) to obtain the aqueous injectable biphasic pharmaceutical composition.
  • an aqueous injectable pharmaceutical composition in the form of a solution, wherein the pharmaceutical composition comprises 200IU/ml of insulin, insulin analogues or derivative thereof and one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml composition of insulin, insulin analogues or derivative thereof and one or more pharmaceutically acceptable excipients, when administered to a subject at the same dose.
  • the pharmaceutical composition has a pH in the range of 6.0 and 8.5.
  • the insulin, insulin analogue or derivative thereof are selected from the group comprising insulin human, insulin isophane (NPH), insulin lispro, insulin glulisine, insulin aspart, Gly(A21) human insulin, Gly(A21) Lys(B28) human insulin, Gly(A21) Lys(B28) Pro(B29) human insulin, Gly(A21) Asp(B28).
  • the insulin, insulin analogues or derivative thereof is insulin human.
  • the one or more pharmaceutically acceptable excipients comprise isotonic agent, complexing agent, buffer, preservative, pH modifying agent, stabilizing agent or mixture thereof.
  • the pharmaceutical composition is administered through subcutaneous, intravenous or intramuscular route to a subject.
  • the pharmaceutical composition is for use in the treatment of type I and type II diabetes mellitus.
  • an aqueous injectable pharmaceutical composition in the form of a suspension, wherein the pharmaceutical composition comprises 200IU/ml of crystals of insulin, insulin analogue or derivative thereof with protamine having particle size in range of 8 ⁇ and 20 ⁇ and one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml composition of crystals of insulin, insulin analogue or derivative thereof with protamine and one or more pharmaceutically acceptable excipients, when administered to a subject at the same dose.
  • the pharmaceutical composition has a pH in the range of 6.0 and 8.5.
  • the insulin, insulin analogue or derivative thereof are selected from the group comprising insulin human, insulin isophane (NPH), insulin lispro, insulin glulisine, insulin aspart, Gly(A21) human insulin, Gly(A21) Lys(B28) human insulin, Gly(A21) Lys(B28) Pro(B29) human insulin, Gly(A21) Asp(B28).
  • the insulin, insulin analogues or derivative thereof is insulin human.
  • the one or more pharmaceutically acceptable excipients comprise isotonic agent, complexing agent, buffer, preservative, pH modifying agent, stabilizing agent or mixture thereof.
  • the pharmaceutical composition is administered through subcutaneous, intravenous or intramuscular route to a subject.
  • the pharmaceutical composition is for use in the treatment of type I and type II diabetes mellitus.
  • Figure 1 is the line graph showing blood glucose levels (mg/dL) after administration of conventional 100 IU/mL product (Huminsulin 30/70) and Example 1 composition (200 IU/mL) to beagle dogs.
  • an aqueous injectable biphasic pharmaceutical composition comprising 200IU/ml of insulin, insulin analogues or derivative thereof, wherein said composition comprises solution of insulin, insulin analogue or derivative thereof and crystals of insulin, insulin analogue or derivative thereof with protamine having particle size in range of 8 ⁇ and 20 ⁇ and optionally, (iii) one or more pharmaceutically acceptable excipients.
  • insulin used herein includes mammalian insulin, human insulin, insulin analogues or derivatives.
  • insulin analogue or “derivative” includes insulin human, insulin isophane (NPH), insulin lispro, insulin glulisine, insulin aspart, Gly(A21) human insulin, Gly(A21) Lys(B28) human insulin, Gly(A21) Lys(B28) Pro(B29) human insulin, Gly(A21) Asp(B28).
  • biphasic herein relates to a composition of insulin, insulin analogue or derivative thereof wherein the composition is a mixture of solution of insulin, insulin analogue or derivative thereof and suspension of crystals of insulin, insulin analogue or derivative thereof.
  • “Pharmaceutical composition” refers to the combination of one or more active ingredients and one or more excipients.
  • pharmaceutically acceptable excipients herein relates to non-active pharmaceutical ingredients which are within the scope of sound medical judgment suitable for use in pharmaceutical products.
  • onset of action refers to the duration of time it takes for a drug's effects to come to prominence upon administration.
  • duration of action refers to the length of time of a drug for which the drug remains effective.
  • dose refers to the quantity of drug to be administered at one time, as a specified amount of medication.
  • subject refers to living mammals which includes human or animal.
  • an aqueous injectable biphasic pharmaceutical composition comprising 200IU/ml of insulin, insulin analogues or derivative thereof, wherein said composition comprises: (i) a solution of insulin, insulin analogue or derivative thereof and (ii) crystals of insulin, insulin analogue or derivative thereof with protamine having particle size in range of 8 ⁇ and 20 ⁇ and optionally, (iii) one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml insulin composition comprising (i) a solution of insulin, insulin analogue or derivative thereof and (ii) crystals of insulin, insulin analogue or derivative thereof with protamine, when administered to a subject at the same dose.
  • an aqueous injectable biphasic pharmaceutical composition comprising 200IU/ml of insulin, insulin analogues or derivative thereof, wherein said composition comprises: (i) a solution of insulin, insulin analogue or derivative thereof and (ii) crystals of insulin, insulin analogue or derivative thereof with protamine having particle size in range of 8 ⁇ and 20 ⁇ and optionally, (iii) one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml insulin composition comprising (i) a solution of insulin, insulin analogue or derivative thereof and (ii) crystals of insulin, insulin analogue or derivative thereof with protamine, when administered to a subject at the same dose, and wherein the pharmaceutical composition has a pH in the range of 6.0 and 8.5, and wherein the solution of insulin, insulin analogue or derivative thereof and the crystals of insulin, insulin analogue or derivative thereof with protamine are present in a volume
  • an aqueous injectable biphasic pharmaceutical composition comprising 200IU/ml of insulin, insulin analogues or derivative thereof, wherein said composition comprises: (i) a solution of insulin, insulin analogue or derivative thereof and (ii) crystals of insulin, insulin analogue or derivative thereof with protamine having particle size in range of 8 ⁇ and 15 ⁇ and optionally, (iii) one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml insulin composition comprising (i) a solution of insulin, insulin analogue or derivative thereof and (ii) crystals of insulin, insulin analogue or derivative thereof with protamine, when administered to a subject at the same dose, and wherein the pharmaceutical composition has a pH in the range of 6.5 and 8 or 7 and 7.5, and wherein the solution of insulin, insulin analogue or derivative thereof and the crystals of insulin, insulin analogue or derivative thereof with protamine are present
  • the pharmaceutical composition may include one or more of the following features.
  • one or more pharmaceutically acceptable excipients comprising isotonic agent, complexing agents, buffer, zinc or salt thereof, preservatives, pH modifying agents, stabilizing agents and combination thereof.
  • isotonic agent is a compound, such as glycerine, are commonly used for such purposes at known concentrations.
  • isotonicity agents are selected from the group comprising glycerol, mannitol, sorbitol, lactose, dextrose, trehalose, sodium chloride, propylene glycol, dimethyl sulfone or mixture thereof.
  • a “complexing agents” as used herein include but not limited to one or more of ethylenediamine tetra-acetic acid or salts thereof, ethylene glycol tetra-acetic acid or salts thereof, protamine or salts thereof or mixture thereof.
  • the protamine is added in the form of protamine salts, wherein the protamine salt is selected from the group comprising protamine sulphate, acetate, ascorbate, benzoate, citrate, formate, fumarate, glycolate and mesylate.
  • preservatives include, but are not limited to, benzoic acid, butylparaben, ethyl paraben, methyl paraben, propylparaben, sodium benzoate, sodium propionate, benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetypyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, 2-Penoxyethanol, Phenyl mercuric nitrate, Thimerosal, meta-cresol or combinations thereof.
  • preservatives are selected form group comprising m-cresol and phenol.
  • the m-cresol is present in the range of 1.20mg/ml to 2. lOmg/ml. Further, the phenol is present in the range of 0.50mg/ml to 0.85mg/ml.
  • buffer as used herein include, but are not limited to, phosphate, acetate, citrate, arginine, disodium hydrogen o-phosphate anhydrous, glycylglycine or TRIS (i.e. 2-amino-2-hydroxymethyl- 1,3 -propanediol) buffer and corresponding salts.
  • the buffer is present in amount of 50mM to 600mM.
  • the zinc is added in the form of zinc salts as stablilizer, wherein the zinc salt is selected from the group comprising zinc acetate, zinc bromide, zinc chloride, zinc fluoride, zinc iodide, zinc oxide and zinc sulphate.
  • Zinc is added in the form of zinc chloride and is present in the range of 0.040mg/ml to 0.08mg/ml.
  • the pH modifying agents as used herein refers to a combination of acid and alkali.
  • the pH modifying agents can be selected from the group comprising of hydrochloric acid, o-phosphoric acid, citric acid, acetic acid, succinic acid, lactic acid, gluconic acid, tartaric acid, 1,2,3,4-butane tetracarboxylic acid, fumaric acid or malic acid.
  • Alkali is selected from the group comprising of sodium hydroxide, potassium hydroxide, sodium hydroxide, ammonium hydroxide, magnesium oxide, calcium hydroxide, calcium carbonate, magnesium carbonate, magnesium aluminum silicates, diethanolamine, monoethanolamine, sodium carbonate, sodium bicarbonate or triethanolamine and combination thereof.
  • an aqueous injectable biphasic pharmaceutical composition comprising 200IU/ml of insulin human, wherein said pharmaceutical composition comprises: (i) a solution of insulin human, (ii) crystals of insulin human with protamine having particle size in range of 8 ⁇ and 15 ⁇ and (iii) pharmaceutically acceptable excipient comprising m-cresol, phenol, glycerol and zinc or salts thereof; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml insulin composition comprising (i) a solution of insulin human and (ii) crystals of insulin human with protamine, when administered to a subject at the same dose.
  • a process of preparing an aqueous injectable biphasic pharmaceutical composition comprising 200IU/ml of insulin, insulin analogues or derivative thereof, wherein said pharmaceutical composition comprises: (i) a solution of insulin, insulin analogue or derivative thereof and (ii) crystals of insulin, insulin analogue or derivative thereof with protamine having particle size in range of 8 ⁇ and 20 ⁇ and optionally, (iii) one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml insulin composition comprising (i) a solution of insulin, insulin analogue or derivative thereof and (ii) crystals of insulin, insulin analogue or derivative thereof with protamine, when administered to a subject at the same dose; wherein said process comprises steps of:
  • step (a) c. mixing about 70% suspension of step (a) with the about 30% solution of step (b) to obtain an aqueous injectable biphasic pharmaceutical composition.
  • a process of preparing an aqueous injectable biphasic pharmaceutical composition comprising 200IU/ml of insulin human, wherein said pharmaceutical composition comprises: (i) a solution of insulin human; (ii) crystals of insulin human with protamine having particle size in range of 8 ⁇ and 15 ⁇ and (iii) pharmaceutically acceptable excipient comprising m-cresol, phenol, glycerol and zinc or salts thereof, wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml insulin composition comprising (i) a solution of insulin human and (ii) crystals of insulin human with protamine, when administered to a subject at the same dose; wherein said process comprises steps of: a.
  • step (a) mixing about 70% of suspension of step (a) with 30% of solution of step (b) to obtain the aqueous injectable biphasic pharmaceutical composition.
  • an aqueous injectable pharmaceutical composition in the form of a solution, wherein the pharmaceutical composition comprises 200IU/ml of insulin, insulin analogues or derivative thereof and one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml composition of insulin, insulin analogues or derivative thereof and one or more pharmaceutically acceptable excipients, when administered to a subject at the same dose.
  • an aqueous injectable pharmaceutical composition in the form of a solution, wherein the pharmaceutical composition comprises 200IU/ml of insulin, insulin analogues or derivative thereof and one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml composition of insulin, insulin analogues or derivative thereof and one or more pharmaceutically acceptable excipients, when administered to a subject at the same dose, and wherein the pharmaceutical composition has a pH in the range of 6.0 and 8.5, and wherein the insulin, insulin analogue or derivative thereof are selected from the group comprising insulin human, insulin isophane (NPH), insulin lispro, insulin glulisine, insulin aspart, Gly(A21) human insulin, Gly(A21) Lys(B28) human insulin, Gly(A21) Lys(B28) Pro(B29) human insulin, Gly(A21) Asp(B28), and wherein the insulin, insulin
  • an aqueous injectable pharmaceutical composition in the form of a solution, wherein the pharmaceutical composition comprises 200IU/ml of insulin, insulin analogues or derivative thereof and one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml composition of insulin, insulin analogues or derivative thereof and one or more pharmaceutically acceptable excipients, when administered to a subject at the same dose, and wherein the pharmaceutical composition has a pH in the range of 6.0 and 8.5, or 6.5 and 8, or 7 and 7.5, and wherein the insulin, insulin analogues or derivative thereof is insulin human, and wherein the one or more pharmaceutically acceptable excipients comprise isotonic agent, complexing agent, buffer, preservative, pH modifying agent, stabilizing agent or mixture thereof, and wherein the pharmaceutical composition is administered through subcutaneous, intravenous or intramuscular route to a subject, and wherein the pharmaceutical composition is for use in the treatment of type I
  • an aqueous injectable pharmaceutical composition in the form of a suspension, wherein the pharmaceutical composition comprises 200IU/ml of crystals of insulin, insulin analogue or derivative thereof with protamine having particle size in range of 8 ⁇ and 20 ⁇ and one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml composition of crystals of insulin, insulin analogue or derivative thereof with protamine and one or more pharmaceutically acceptable excipients, when administered to a subject at the same dose.
  • an aqueous injectable pharmaceutical composition in the form of a suspension wherein the pharmaceutical composition comprises 200IU/ml of crystals of insulin, insulin analogue or derivative thereof with protamine having particle size in range of 8 ⁇ and 20 ⁇ and one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml composition of crystals of insulin, insulin analogue or derivative thereof with protamine and one or more pharmaceutically acceptable excipients, when administered to a subject at the same dose, and wherein the pharmaceutical composition has a pH in the range of 6.0 and 8.5, and wherein the insulin, insulin analogue or derivative thereof are selected from the group comprising insulin human, insulin isophane (NPH), insulin lispro, insulin glulisine, insulin aspart, Gly(A21) human insulin, Gly(A21) Lys(B28) human insulin, Gly(A21) Lys(B28) Pro(B29
  • an aqueous injectable pharmaceutical composition in the form of a suspension wherein the pharmaceutical composition comprises 200IU/ml of crystals of insulin, insulin analogue or derivative thereof with protamine having particle size in range of 8 ⁇ and 15 ⁇ and one or more pharmaceutically acceptable excipients; wherein said pharmaceutical composition provides similar onset of action and longer duration of action as compared to lOOIU/ml composition of crystals of insulin, insulin analogue or derivative thereof with protamine and one or more pharmaceutically acceptable excipients, when administered to a subject at the same dose, and wherein the pharmaceutical composition has a pH in the range of 6.0 and 8.5 or 6.5 and 8 or 7 and 7.5, and wherein the insulin, insulin analogues or derivative thereof is insulin human, and wherein the one or more pharmaceutically acceptable excipients comprise isotonic agent, complexing agent, buffer, preservative, pH modifying agent, stabilizing agent or mixture thereof, and wherein the pharmaceutical composition is administered through subcutaneous, intravenous or intramus
  • EXAMPLE 1 An aqueous injectable biphasic pharmaceutical composition containing 200 IU/mL insulin human.
  • Step 1 Preparing of protamine insulin human suspension
  • EXAMPLE 2 Comparison of hypoglycemic effect of EXAMPLE 1 composition with commercial huminsulin 30/70 (lOOIU/ml) composition.
  • mice were treated with single subcutaneous (s.c.) injection of the example 1 composition and huminsulin 30/70 composition at the dose of 0.35 IU/kg body weight in a loose skin over neck region. Blood glucose levels were measured at 0.25, 0.5, 1, 2, 3, 4, 5 and 6h post-dose.
  • composition of Example 1 showed similar onset and longer duration of action as compared with commercial huminsulin 30/70 (lOOIU/mL) composition marketed by Eli Lilly. It is evident from table 2, that the AUC for example 1 composition is 117 and AUC for commercial huminsulin 30/70 (lOOIU/ml) composition is 75. Also the blood glucose level of example 1 composition at 4hr, 5hr and 6hr is 50, 55 and 60 mg///dL respectively and blood glucose level of commercial huminsulin 30/70 (lOOIU/ml) composition at 4hr, 5hr and 6hr is 70, 75 and 80 mg/dL respectively. This data confirms that the better glucose lowering effect of composition of example 1 as compared to commercial huminsulin 30/70 (lOOIU/ml) composition.
  • EXAMPLE 3 Comparison of particle size of example 1 composition with commercial huminsulin 30/70 (lOOIU/ml) composition.
  • example 1 of present invention 200IU/mL insulin human
  • the pharmaceutical composition of example 1 of present invention has larger particle size (8-12 ⁇ ) of crystals of insulin human with protamine as compared to the commercial huminsulin 30/70 (lOOIU/mL) composition.
  • EXAMPLE 4 Pharmaceutical compositions containing 200 IU/mL insulin human
  • Insulin human and zinc oxide was suspended in water for injection and dissolved by small portion of IN HC1. Further phenol, m-cresol, and glycerol were dissolved in small portion of water for injection. Both the solutions were mixed and the pH was adjusted to 2.9-3.3. In small portion of water for injection citric acid monohydrate and Tri-Sodium Citrate Dihydrate was dissolved and added to above solution, pH of the final composition was adjusted to 7.2 to 7.45 by IN HC1 or IN NaOH.
  • EXAMPLE 5 An aqueous injectable biphasic pharmaceutical composition containing 200 IU/mL insulin human.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique biphasique injectable aqueuse comprenant 200 UI/ml d'insuline, d'analogues d'insuline ou d'un dérivé de ceux-ci, ladite composition comprenant (i) une solution d'insuline, d'analogue d'insuline ou d'un dérivé de ceux-ci et (ii) des cristaux d'insuline, d'analogue d'insuline ou d'un dérivé de ceux-ci avec une protamine présentant une taille de particule se situant dans la plage de 8 à 20 µm et, éventuellement, (iii) un ou plusieurs excipients de qualité pharmaceutique. s.
PCT/IB2017/051584 2016-03-21 2017-03-18 Composition pharmaceutique biphasique d'insuline humaine Ceased WO2017163159A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621009801 2016-03-21
IN201621009801 2016-03-21

Publications (1)

Publication Number Publication Date
WO2017163159A1 true WO2017163159A1 (fr) 2017-09-28

Family

ID=58692532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/051584 Ceased WO2017163159A1 (fr) 2016-03-21 2017-03-18 Composition pharmaceutique biphasique d'insuline humaine

Country Status (1)

Country Link
WO (1) WO2017163159A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823591A4 (fr) * 2018-07-16 2022-05-04 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Insuline humaine injectable micronisée

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002633A1 (fr) 1986-10-20 1988-04-21 Novo Industri A/S Preparatiosn d'insuline avec du zinc et des protamines
WO1995000550A1 (fr) * 1993-06-21 1995-01-05 Novo Nordisk A/S Cristaux d'insuline asp?b28¿
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547930A (en) 1993-06-21 1996-08-20 Novo Nordisk A/S AspB28 insulin crystals
WO1997048413A1 (fr) * 1996-06-20 1997-12-24 Novo Nordisk A/S Preparations a base d'insuline contenant des glucides
EP0911035A2 (fr) * 1997-10-24 1999-04-28 Eli Lilly And Company Compositions non solubles d' insuline
WO1999048520A1 (fr) 1998-03-24 1999-09-30 Joergensen Klavs Holger Nouvelle preparation d'insuline humaine a action prolongee
WO2003053460A1 (fr) 2001-12-19 2003-07-03 Eli Lilly And Company Compositions cristallines pour reguler la glycemie
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
WO2006037789A1 (fr) * 2004-10-05 2006-04-13 Novo Nordisk A/S Formulation pharmaceutique comprenant de l'insuline cristallisee et de l'insuline en solution
WO2011156476A2 (fr) 2010-06-08 2011-12-15 Biodel Inc. Insuline présentant un profil de libération basal
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002633A1 (fr) 1986-10-20 1988-04-21 Novo Industri A/S Preparatiosn d'insuline avec du zinc et des protamines
WO1995000550A1 (fr) * 1993-06-21 1995-01-05 Novo Nordisk A/S Cristaux d'insuline asp?b28¿
US5547930A (en) 1993-06-21 1996-08-20 Novo Nordisk A/S AspB28 insulin crystals
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5747642A (en) * 1994-06-16 1998-05-05 Eli Lilly And Company Monomeric insulin analog formulations
WO1997048413A1 (fr) * 1996-06-20 1997-12-24 Novo Nordisk A/S Preparations a base d'insuline contenant des glucides
EP0911035A2 (fr) * 1997-10-24 1999-04-28 Eli Lilly And Company Compositions non solubles d' insuline
WO1999048520A1 (fr) 1998-03-24 1999-09-30 Joergensen Klavs Holger Nouvelle preparation d'insuline humaine a action prolongee
WO2003053460A1 (fr) 2001-12-19 2003-07-03 Eli Lilly And Company Compositions cristallines pour reguler la glycemie
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
WO2006037789A1 (fr) * 2004-10-05 2006-04-13 Novo Nordisk A/S Formulation pharmaceutique comprenant de l'insuline cristallisee et de l'insuline en solution
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
WO2011156476A2 (fr) 2010-06-08 2011-12-15 Biodel Inc. Insuline présentant un profil de libération basal

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823591A4 (fr) * 2018-07-16 2022-05-04 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Insuline humaine injectable micronisée

Similar Documents

Publication Publication Date Title
RU2311922C2 (ru) Свободные от цинка и обедненные цинком инсулиновые композиции с повышенной стабильностью
US20150174209A1 (en) Insulin-pramlintide compositions and methods for making and using them
JP6422855B2 (ja) インスリンおよびインスリン類似体の薬物動態及び薬力学、ならびに注射部位の疼痛を調節するためのマグネシウム組成物
AU2013365945B2 (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
Lindholm New insulins in the treatment of diabetes mellitus
US8637458B2 (en) Insulin with a stable basal release profile
CA2487585A1 (fr) Formulations de peptides agonistes de l'amyline
JP2017203042A (ja) インスリン−亜鉛錯体の調製方法
AU2013249495A1 (en) Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
EP2590667A1 (fr) Compositions et procédés pour la modulation de la pharmacocinétique et de la pharmacodynamie de l'insuline
WO2017163159A1 (fr) Composition pharmaceutique biphasique d'insuline humaine
WO2016001862A1 (fr) Formulations à libération prolongée d'insulines
US12343383B2 (en) High concentration insulin formulation
WO2018153506A1 (fr) Composition d'insuline à action rapide contenant un sel d'acide citrique
BR112015011179B1 (pt) Composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17722503

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17722503

Country of ref document: EP

Kind code of ref document: A1